The relationship between prognostic and predictive factors in the management of breast cancer

Breast Cancer Research and Treatment

Volumn 52, Issue 1-3, 1998, Pages 261-288

  Henderson, I Craig ^a,b   Patek, Anthony J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ALZA CORPORATION   (United States)

Author keywords

c erbB2; Cut point; Estrogen receptor; Predictive; Prognostic

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

BREAST CANCER; CANCER GRADING; CELL INVASION; HUMAN; MEDICAL DECISION MAKING; MENOPAUSE; ONCOGENE NEU; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT PLANNING; TUMOR VOLUME;

EID: 0032412818     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006141703224     Document Type: Review

References (292)

1. Henderson IC, Canellos GP: Cancer of the breast: the past decade. N Engl J Med 302:17-30/78-90, 1980
2. Sasaki GH, Leung BS, Fletcher WS: LevoDopa test and estrogen receptor assay in prognosticating responses of patients with advanced cancer of the breast to endocrine therapy. Ann Surg 183:392-396, 1976
3. Sluyser M, Van Nie R: Estrogen receptor content and hormone-responsiveness of growth of mouse mammary tumors. Cancer Res 34:3253-3257, 1974
4. Byar D, Sears M, McGuire W: Relationship between estrogen receptor values and clinical data in predicting the response to endocrine therapy for patients with advanced breast cancer. Eur J Cancer 15:299-310, 1979
5. Cooke T, George D, Shields R, Maynard P, Griffiths K: Oestrogen receptors and prognosis in early breast cancer. Lancet i:995-997, 1979
6. Fletcher W, Leung B, Davenport C: The prognostic significance of estrogen receptors in human breast cancer. Am J Surg 135:372-374, 1978
7. Hahnel R, Woodings T, Vivian AB: Prognostic value of estrogen receptors in primary breast cancer. Cancer 44:671-675, 1979
8. Holdaway IM, Mountjoy KG: Progesterone and oestrogen receptors in human breast cancer. Austr NZ J Med 8:630-638, 1978
9. Kern WH: Morphologic and clinical aspects of estrogen receptors in carcinoma of the breast. Surg Gynecol Obstet 148:240-242, 1979
10. Knight WA III, Livingston RB, Gregory EJ, McGuire WL: Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37:4669-4671, 1977
11. Lippman ME, Allegra JC, Thompson EG, Simon R, Barlock A, Green L, Huff KK, Do HMT, Aitken SC, Warren R: The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 298:1223-1228, 1978
12. Hayes D: Serum (circulating) tumor markers for breast cancer. Rec Results Cancer Res 140:101-131, 1996
13. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene. Science 235:177-182, 1987
14. Spiegel D, Bloom JR, Kraemer HC, Gottheil E: Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 2:888-891, 1989
15. Kogon MM, Biswas A, Pearl D, Carlson RW, Spiegel D: Effects of medical and psychotherapeutic treatment on the survival of women with metastatic breast carcinoma. Cancer 80:225-230, 1997
16. Spiegel D: Cancer and depression [review]. Br J Psych Suppl 30:109-116, 1996
17. Gaspanni G, Bevilacqua P, Dal Fior S, Panizzoni GA, Favretto S, Visona A, Meli S: Characterization of node-negative breast cancer by clinico-pathologic and biologic factors. Anticancer Res 10:205-208, 1990
18. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71-85, 1992
19. Henderson IC: Adjuvant systemic therapy for early breast cancer. Cancer 74:401-409, 1994
20. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996
21. Fisher B, Redmond C, Fisher ER, Caplan R: Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: Findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 6:1076-1087, 1988
22. Pichon MF, Broet P, Magdelenat H, Delarue JC, Spyratos F, Basuyau JP, Saez S, Rallet A, Courriere P, Millon R, Asselain B: Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br J Cancer 73:1545-1551, 1996
23. Osborne CK: Receptors. In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds) Breast Diseases, Second Edition. Lippincott, Philadelphia, 1991, pp 301-325
24. Press M, Hung G, Godolphin W, Slamon D: Sensitivity of HER2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54:2771-2777, 1994
25. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
26. Tandon AK, Clark GM, Chamness GU, Ullrich A, McGuire WL: HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7:1120-1128, 1989
27. Thor A, Schwartz L, Koerner F, Edgerton S, Skates S, Yin S, McKenzie SJ, Panicali DL, Marks PJ, Fingert HJ, Wood WC: Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res 49:7147-7152, 1989
28. Kallioniemi O-P, Holli K, Visakorpi T, Koivula T, Helin H, Isola J: Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49:650-655, 1991
29. Lovekin C, Ellis I, Locker A, Robertson J, Bell J, Nicholson R, Gullick W, Elston C, Blamey R: c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 63:439-443, 1991
30. McCann A, Dervan P, O'Regan M, Codd M, Gullick W, Tobin B, Carney D: Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 51:3296-3303, 1991
31. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L, McGuire WL: HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10:599-605, 1992
32. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam D-M, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Burki K, Castiglione M, Collins J, Lindtner J, Senn H-J: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10:1049-1056, 1992
33. Noguchi M, Koyasaki N, Ohta N, Kitagawa H, Earashi M, Thomas M, Miyazaki I, Mizukami Y: c-erbB-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer. Cancer 69:2953-2960, 1992
34. Tanner B, Freidberg T, Itze M, Beck T, Oesch F, Knapstein P-G: c-erbB-2 oncogene expression in breast carcinoma: analysis by S1 nuclease protection assay and immunohistochemistry in relation to clinical parameters. Gynecol Oncol 47:228-233, 1992
35. Yuan J, Hennessy C, Givan A, Corbett I, Henry J, Sherbet G, Lennard T: Predicting outcome for patients with node negative breast cancer; a comparative study of the value of flow cytometry and cell image analysis for determination of DNA ploidy. Br J Cancer 65:461-465, 1992
36. Bianchi S, Paglierani M, Zampi G, Cardona G, Cataliotti L, Bonardi R, Ciatto S: Prognostic significance of c-erbB-2 expression in node-negative breast cancer. Br J Cancer 67:625-629, 1993
37. Press M, Pike M, Chazin V, Hung F, Udove J, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R, Paterson M, Slamon D: Her2-neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53:4960-4970, 1993
38. Gasparini G, Gullick W, Maluta S, Palma P, Caffo O, Leonardi E, Boracchi P, Pozza F, Lemoine N, Bevilacqua P: c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma - an immunocytochemical study. Eur J Cancer 30A:16-22, 1994
39. Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D'Antonio A, Bianco A, De Placido S: c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14:2702-2708, 1996
40. Molland J, Barraclough B, Gebski V, Milliken J, Bilous M: Prognostic significance of c-erbB-2 oncogene in axillary node-negative breast cancer. Aust NZ J Surg 66:64-70, 1996
41. Andrulis I, Bull S, Blackstein M, et al: neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J Clin Oncol 16:1340-1349, 1998
42. Sjögren S, Inganäs M, Lindgren A, Holmberg L, Bergh J: Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 16:462-469, 1998
43. Giai M, Roagna R, Ponzone R, de Bortoli M, Dati C, Sismondi P: Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer. Anticancer Res 14:1441-1450, 1994
44. Quenel N, Wafflart J, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, Coindre J: The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 35:283-291, 1995
45. Borg Å, Tandon A, Sigurdsson H, Clark G, Fernö M, Fuqua S, Killander D, McGuire W: Her2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50:4332-4337, 1990
46. Têtu B, Brisson J: Prognostic significance of HER2/neu oncoprotein expression in node-positive breast cancer. Cancer 73:2359-2365, 1994
47. Muss HB, Thor A, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DP, Wood WC, Barcos M, Henderson IC: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994
48. Hartmann L, Ingle J, Wold L, Farr GHJ, Grill J, Su J, Maihle N, Krook J, Witzig T, Roche P: Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer 74:2956-2963, 1994
49. Tsuda H, Sakamaki C, Tsugane S, Fukutomi T, Hirohashi S: A prospective study of the significance of gene and chromosome alterations as prognostic indicators of breast cancer patients with lymph node metastases. Breast Cancer Res Treat 48:21-32, 1998
50. Lippman ME, Weisenthal LM, Paik SM, Nagourney RA, Kern DH: erbB-2 positive specimens from previously-untreated breast cancer patients have in vitro drug resistance profiles which resemble profiles of specimens obtained from patients who have previously failed combination chemotherapy. Proc ASCO 9:24, 1990
51. Thor A, Budman D, Berry D, Muss H, Kute T, Barcos M, Cirrincione C, Edgerton S, Weiss R, Ferree C, Allred C, Wood W, Frei E III, Henderson I, Norton L, Liu E: Selecting patients for higher dose adjuvant CAF: c-erbB-2, p53, dose and dose intensity in stage II, node+ breast cancer (CALGB 8869 and 8541). Proc ASCO 16:A452, 1997
52. Howell A, Harland RNL, Bramwell VHC, Swindell R, Barnes DM, Redford J, Wilkinson MJS, Crowther D, Sellwood RA: Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet i:588-591, 1984
53. Fisher ER, Gregorio R, Redmond C, Dekker A, Fisher B: Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol No. 4). Am J Clin Pathol 65:21-30, 1976
54. Fisher E, Swamidoss S, Lee C, Rockette H, Redmond C, Fisher B: Detection and significance of occult axillary node metastases in patients with invasive breast cancer. Cancer 42:2025-2031, 1978
55. Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER: Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. Cancer 52:1551-1557, 1983
56. Rosen PP, Saigo PE, Braun DW, Weathers E, Fracchia AA, Kinne DW: Axillary micro- and macrometastases in breast cancer. Ann Surg 194:585-591, 1981
57. Thorpe SM, Rochefort H, Garcia M, Freiss G, Christensen IJ, Khalaf S, Paolucci F, Pau B, Rasmussen BB, Rose C: Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 49:6008-6014, 1989
58. Tandon AK, Clark GM, Chamness GC, Chirgwin JM, McGuire WL: Cathepsin D and prognosis in breast cancer. N Engl J Med 322:297-302, 1990
59. Ravdin PM, Tandon AK, Allred DC, Clark GM, Fuqua SAW, Hilsenbeck SH, Chamness GC, Osborne CK: Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol 12:467-474, 1994
60. Rockette HE, Caplan RJ: Heterogeneous treatment effects - strategies for subgroup analysis in clinical trials. Rec Results Cancer Res 111:49-54, 1988
61. Hilsenbeck SG, Ravdin PM, de Moor CA, Osborne CK, Clark GM: Paradoxical decreases in prognostic utility as datasets mature: time-dependent lack of proportional hazards in prognostic factors in primary breast cancer [abstract]. Breast Cancer Res Treat 37:35, 1996
62. Hilsenbeck S, Clark G, McGuire W: Why do so many prognostic factors fail to pan out? Breast Cancer Res Treat 22:197-206, 1992
63. McGuire WL, Clark GM: Prognostic factors and treatment decisions in axillary node-negative breast cancer. N Engl J Med 326:1756-1761, 1992
64. Clark G, Hilsenbeck S, Ravdin P, Di Laurentiis M, Osborne C: Prognostic factors: Rationale and methods of analysis and integration. Breast Cancer Res Treat 32:105-112, 1994
65. Henderson IC: Prognostic factors. In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds) Breast Diseases (2nd ed). Lippincott, Philadelphia, 1991, pp 332-346
66. Levine M, Browman G, Gent M, Roberts R, Goodyear M: When is a prognostic factor useful?: a guide for the perplexed. J Clin Oncol 9:348-356, 1991
67. McGuire WL, Tandon AK, Allred C, Chamness GC, Clark GM: How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 82:1006-1015, 1990
68. Gasparini G, Pozza F, Harris A: Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 85: 1206-1219, 1993
69. Koenders P, Beex L, Kienhui C, Kloppenborg P, Benraad T: Epidermal growth factor receptor and prognosis in human breast cancer: a prospective study. Breast Cancer Res Treat 25:21-27, 1993
70. Seshadri R, McLeay W, Horsfall D, McCaul K: Prospective study of the prognostic significance of epidermal growth factor receptor in primary breast cancer. Int J Cancer 69:23-27, 1996
71. Pujol P, Maudelonde T, Daures J-P, Rouanet P, Brouillet J-P, Pujol H, Rochefort H: A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol. Cancer 71:2006-2012, 1992
72. Ciocca D, Clark G, Tandon A, Fuqua S, Welch W, McGuire W: Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer. J Natl Cancer Inst 85:570-574, 1993
73. Ravdin PM, Clark GM: A practical application of neural network analysis for predicting outcome of individual breast cancer patients. Breast Cancer Res Treat 22:285-293, 1992
74. Ravdin PM, Clark GM, Hilsenbeck SG, Owens MA, Vendely P, Pandian MR, McGuire WL: A demonstration that breast cancer recurrence can be predicted by neural network analysis. Breast Cancer Res Treat 21:47-53, 1992
75. Masters JRW, Camplejohn RS, Millis RR, Rubens RD: Histological grade, elastosis, DNA ploidy and the response to chemotherapy of breast cancer. Br J Cancer 55:455-457, 1987
76. Remvikos Y, Beuzeboc P, Zajdela A, Voillemot N, Magdelenat H, Pouillart P: Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst 81:1383-1387, 1989
77. Fisher ER, Redmond C, Fisher B: Pathologic findings from the National Surgical Adjuvant Breast Cancer Project: VIII. Relationship of chemotherapeutic responsiveness to tumor differentiation. Cancer 51:181-191, 1983
78. Hietanen P, Blomqvist C, Wasenius VM, Niskanen E, Franssila K, Nordling S: Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer? Br J Cancer 71:1029-1032, 1995
79. Chevillard S, Pouillart P, Beldjord C, Asselain B, Beuzeboc P, Magdelenat H, Vielh P: Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 77:292-300, 1996
80. Kute TE, Quadri Y, Muss H, Zbieranski N, Cirrincione C, Berry DA, Barcos M, Thor AP, Liu E, Koerner F, et al: Flow cytometry in node-positive breast cancer: Cancer and Leukemia Group B protocol 8869. Cytometry 22:297-306, 1995
81. Sulkes A, Livingston RB, Murphy WK: Tritiated thymidine labeling index and response in human breast cancer. J Natl Cancer Inst 62:513-515, 1979
82. Silvestrini R, Daidone MG, Valagussa P, Salvadori B, Rovini D, Bonadonna G: Cell kinetics as a prognostic marker in locally advanced breast cancer. Cancer Treat Rep 71:375-379, 1987
83. Clark GM, Mathieu MC, Owens MA, Dressler LG, Eudey L, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff MD, et al: Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. J Clin Oncol 10:428-432, 1992
84. Bonadonna G, Valagussa P, Tancini G, Rossi A, Brambilla C, Zambetti M, Bignami P, Di Fronzo G, Silvestrini R: Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer. NCI Monogr 1:45-49, 1986
85. Dressler LG, Eudey L, Gray R, Tormey DC, McGuire WL, Gilchrist KW, Clark GM, Osborne CK, Mansour EG, Abeloff MD: Prognostic potential of DNA flow cytometry measurements in node-negative breast cancer patients: Preliminary analysis of an Intergroup study (INT 0076). JNCI Monographs 11:167-72, 1992
86. O'Reiily SM, Barnes DM, Camplejohn RS, Millis RR, Bartkova J, Rubens RD, Richards MA: The relationship between c-erbB-2 expression, S-phase fraction (SPF) and prognosis in breast cancer. Proc ASCO 9:18, 1990
87. Stal O, Sullivan S, Wingren S, Skoog L, Rutqvist LE, Carstensen JM, Nordenskjold B: c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 31A:2185-2190, 1995
88. Gilchrist KW, Kalish L, Gould VE, Hirschl S, Imbraglia JE, Levy WM, Patchefsky AS, Penner DW, Pickren J, Roth JA, Schinella RA, Schwartz IS, Wheeler JE: Interobserver reproducibility of histopathological features in Stage II breast cancer: An ECOG study. Breast Cancer Res Treat 5:3-10, 1985
89. Spyratos F, Briffod M, Tubiana-Hulin M, Andrieu C, Mayras C, Pallud C, Lasry S, Rouesse J: Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma. II. DNA flow cytometry changes during chemotherapy, tumor regression, and short-term follow-up. Cancer 69:470-475, 1992
90. O'Reilly SM, Richards MA: Is flow cytometry a useful investigation in breast cancer? Eur J Cancer 28:504-507, 1992
91. Briffod M, Spyratos F, Tubiana-Hulin M, Pallud C, Mayras C, Filleul A, Rouesse J: Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma: cytomorphologic changes, initial tumor ploidy, and tumor regression. Cancer 63:631-637, 1989
92. Barnes DM: Cyclin D1 expression and prognosis in mammary carcinoma. Proc AACR 37:A1418, 1996
93. Bates S, Parry D, Bonetta L, Vousden K, Dickson C, Peters G: Absence of cyclin D/cdk complexes in cells lacking functional retinoblastoma protein. Oncogene 9:1633-1640, 1994
94. Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G, Barnes D: Cyclin D1 and prognosis in human breast cancer. Int J Cancer 69:92-99, 1996
95. McIntosh G, Anderson J, Milton I, Steward M, Parr A, Thomas M, Henry J, Angus B, Lennard T, Horne C: Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 11:885-891, 1995
96. Michalides R, Hageman P, van Tinteren H, Houben L, Wientjens E, Klompmaker R, Peterse J: A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer 73:728-734, 1996
97. Pelosio P, Barbareschi M, Benoldi E, Marchetti A, Verderio P, Caffo O, Bevilacqua P, Borracchi P, Buttitta F, Barbazza R, Palma P, Gasparini G: Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. Ann Oncol 7:695-703, 1996
98. Seshadri R, Lee C, Hui R, McCaul K, Horsfall D, Sutherland R: Cyclin D1 amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clin Cancer Res 2:1174-1184, 1996
99. van Diest PJ, Michalides RJ, Jannink J, van der Valk P, Peterse HL, de Jong JS, Meijer CJ, Baak JP: Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. Am J Pathol 150:705-711, 1997
100. Silvestrini R, Benini E, Veneroni S, Daidone M, Tomasic G, Squicciarini P, Salvadori B: p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 14:1604-1610, 1996
101. I, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer. J Natl Cancer Inst 89:639-45, 1997
102. van Slooten H-J, Clahsen P, van Dierendonck J, Duval C, Pallud C, Mandard A-M, Delobelle-Deroide A, van de Velde C, van de Vijver M: Expression of BCL-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Brit J Cancer 74:78-85, 1996
103. Lê M, Mathieu M, Llombart-Cussac A, Abd el Al H, Spielman M, Riou G: Prognostic value of bcl-2 expression in operable breast cancer patients. Proc ASCO 16:A483, 1997
104. Schroeder W, Biersterfield S, Zillessen S, Rath W: Epidermal growth factor receptor - immunohistochemical detection and clinical significance for treatment of primary breast cancer. Anticancer Res 17:2799-2802, 1997
105. Torregrosa D, Bolufer P, Lluch A, López J, Barragán E, Ruiz A, Guillem V, Munárriz B, García Conde J: Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status. Clin Chim Acta 262:99-119, 1997
106. Hawkins R, Tesdale A, Killen M, Jack W, Chetty U, Dixon J, Hulme M, Prescott R, McIntyre M, Miller W: Prospective evaluation of prognostic factors in operable breast cancer. Br J Cancer 74:1469-1478, 1996
107. Bolla M, Chedin M, Colonna M, Marron-Charrière J, Rostaing-Puissant B, Pasquier D, Panh M, Winckel P, Chambaz E: Lack of prognostic value, of epidermal growth factor receptor in a series of 229 T1/T2, N0/N1 breast cancers, with well defined prognostic parameters. Breast Cancer Res Treat 29:265-270, 1994
108. Delarue JC, Friedman S, Mouriesse H, May-Levin F, Sancho-Garnier H, Contesso G: Epidermal growth factor receptor in human breast cancers: correlation with estrogen and progesterone receptors. Breast Cancer Res Treat 11:173-178, 1988
109. Fox SB, Smith K, Hollyer J, Greenhall M, Hastrich D, Harris AL: The epidermal growth factor receptor as a prognostc marker: Results of 370 patients and review of 3009 patients. Breast Cancer Res Treat 29:41-49, 1994
110. Gasparini G, Borazzio P, Bevilacqua P, Mezzetti M, Pozza F, Weidner N: A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma. Breast Cancer Res Treat 29:59-71, 1994
111. Klijn J, Look M, Portengen H, Alexieva-Figusch J, van Putten W, Foekens J: The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study. Breast Cancer Res Treat 29:73-83, 1994
112. Nicholson R, McClelland R, Gee J, Manning D, Cannon P, Robertson J, Ellis I, Blamey R: Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat 29:117-125, 1994
113. Noguchi M, Mizukami Y, Kinoshita K, Earashi M, Thomas M, Miyazaki I: The prognostic significance of epidermal growth factor receptor expression in breast cancer. Surg Today 24:889-894, 1994
114. Spyratos F, Martin P, Hacène K, Andrieu C, Romain S, Floiras J, Magdelènat H: Prognostic value of a solubilized fraction of EGF receptors in primary breast cancer using an immunoenzymatic assay - a retrospective study. Breast Cancer Res Treat 29:85-95, 1994
115. Toi M, Tominaga T, Osaki A, Toge T: Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytochemical study. Breast Cancer Res Treat 29:51-58, 1994
116. Iwase H, Kobayashi S, Itoh Y, Kuzushima T, Yamashita H, Iwata H, Naito A, Yamashita T, Itoh K, Masaoka A: Clinical value of enzyme immunoassay of epidermal growth factor receptor in human breast cancer. Breast Cancer Res Treat 28:215-221, 1993
117. Murray P, Barrett-Lee P, Travers M, Luqmani Y, Powles T, Coombes R: The prognostic significance of transforming growth factors in human breast cancer. Br J Cancer 67:1408-1412, 1993
118. Osaki A, Toi M, Yamada H, Kawami H, Kuroi K, Toge T: Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. Am J Surg 164:323-326, 1992
119. Sauer R, Schauer A, Rauschecker H, Schumacher M, Gatzemeier W, Sauerbrei W, Dunst J, Seegenschmiedt M, Marx D, et al: Breast preservation versus mastectomy in early breast cancer - 1991 update of the GBSG 1 - protocol and prognostic factors. Strahl Onkol 168:191-202, 1992
120. Nicholson S, Sainsbury JRC, Halcrow P, Kelly P, Angus B, Wright C, Henry J, Farndon J, Harris A: Epidermal growth factor receptor (EGFr); results of a 6-year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 63:146-150, 1991
121. Toi M, Osaki A, Yamada H, Toge T: Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. Eur J Cancer 27:977-980, 1991
122. Toi M, Nakamura T, Mukaida H, Wada T, Osaki A, Yamada H, Toge T, Niimoto M, Hattori T: Relationship between epidermal growth factor receptor status and various prognostic factors in human breast cancer. Cancer 65:1980-1984, 1990
123. Lewis S, Locker A, Todd J, Bell J, Nicholson R, Elston C, Blamey R, Ellis I: Expression of epidermal growth factor receptor in breast carcinoma. J Clin Pathol 43:385-389, 1990
124. Spyratos F, Delarue J.-C, Andrieu C, Lidereau R, Champéme M-H, Hacène K, Brunet M: Epidermal growth factor receptors and prognosis in primary breast cancer. Breast Cancer Res Treat 17:83-89, 1990
125. Foekens J, Portengen H, van Putten W, Trapman A, Reubi J-C, Alexieva-Figusch J, Klijn J: Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 49:7002-7009, 1989
126. Grimaux M, Romain S, Remvikos Y, Martin PM, Magdelenat H: Prognostic value of epidermal growth factor receptor in node-positive breast cancer. Breast Cancer Res Treat 14:77-90, 1989
127. Harris AL, Nicholson S, Sainsbury JRC, Farndon J, Wright C: Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones and interactions with neu. J Steroid Biochem 34:123-131, 1989
128. Sainsbury JRC, Nicholson S, Farndon JR, Harris AL: Epidermal growth factor receptor (EGFr) status. A clinically useful prognostic indicator in axillary node negative breast cancer [abstract]. Breast Cancer Res Treat 14:133, 1989
129. Costa S, Stamm H, Alemendral A, Ludwig H, Wyss R, Fabbro D, Ernst A, Takahashi A, Eppenberger U: Predictive value of EGF receptor in breast cancer. Lancet ii:1258, 1988
130. Nicholson S, Halcrow P, Sainsbury JRC, Angus B, Chambers P, Farndon JR, Harris AL: Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer. Br J Cancer 58:810-814, 1988
131. Rios MA, Macias A, Perez R, Lage A, Skoog L: Receptors for epidermal growth factor and estrogen as predictors of relapse in patients with mammary carcinoma. Anticancer Res 8:173-176, 1988
132. Sainsbury JRC, Farndon JR, Needham GK, Harris AL, Malcolm AJ: Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet i:1398-1402, 1987
133. Schwartz L, Koerner F, Edgerton S, Sawicka J, Rio M-C, Bellocq J-P, Chambon P, Thor A: pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res 51:624-628, 1991
134. Henry J, Piggott N, Mallick U, Nicholson S, Farndon J, Westley B, May F: pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. Br J Cancer 63:615-622, 1991
135. Hurlimann J, Gebhard S, Gomez F: Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas. Histopathology 23:239-248, 1993
136. Luqmani YA, Ricketts D, Ryall G, Turnbull L, Law M, Coombes RC: Prediction of response to endocrine therapy in breast cancer using immunocytochemical assays for pS2, oestrogen receptor and progesterone receptor. Int J Cancer 54:619-623, 1993
137. Wilson Y, Rhodes M, Ibrahim N, Padfield C, Cawthorn S: Immunocytochemical staining of pS2 protein in fine-needle aspirate from breast cancer is an accurate guide to response to tamoxifen in patients aged over 70 years. Br J Surg 81:1155-1158, 1994
138. Soubeyran I, Quènal N, Coindre J-M, Bonichon F, Durand M, Wafflart J, Mauriac L: pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients. Brit J Cancer 74:1120-1125, 1996
139. Besse G, Kwiatkowski F, Gaillard G, Daver A, Dalifard I, Basuyau J, Brunelle P, Wafflart J, Angibeau R, Auvray E, Goussard J: Rôle prognostique de la protéine pS2 dans 1065 cas de cancer du sein. Étude multicentrique. Bull Cancer 81:289-296, 1994
140. 1. Br J Cancer 74:1458-1465, 1996
141. Predine J, Spyratos F, Prud'homme J, Andrieu C, Hacene K, Brunet M, Pallud C, Milgrom E: Enzymelinked immunosorbent assay of pS2 in breast cancers, benign tumors, and normal breast tissues. Cancer 69:2116-2123, 1992
142. Crombach G, Ingerhorst A, Göhring U-J, Scharl A, Möbus V, Schaeffer H-J: Expression of pS2 protein in breast cancer. Arch Gynecol Obstet 253:183-192, 1993
143. Göhring U-J, Scharl A, Ahr A: Immunohistochemical detection of receptors, proteases, tumour suppressor proteins and proliferating markers as prognostic indicators for primary breast cancer patients. Geburtsch Frauenheilk 56:177-183, 1996
144. Thor A, Koerner F, Edgerton S, Wood W, Stracher M, Schwartz L: pS2 expression in primary breast carcinomas: Relationship to clinical and histological features and survival. Breast Cancer Res Treat 21:111-119, 1992
145. Foekens J, Schmitt M, van Putten W, Peters H, Kramer M, Jänicke F, Klijn J: Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12:1648-1658, 1994
146. Foekens J, Rio M-C, Seguin P, van Putten W, Fauque J, Nap M, Klijn J, Chambon P: Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 50:3832-3837, 1990
147. Gion M, Mione R, Pappagallo GL, Gatti C, Nascimben O, Bari M, Leon AE, Vinante O, Bruscagnin G: pS2 in breast cancer - alternative or complementary tool to steroid receptor status? Evaluation of 446 cases. Br J Cancer 68:374-379, 1993
148. Stonelake PS, Baker PG, Gillespie WM, Dunn JA, Spooner D, Morrison JM, Bundred NJ, Oates GD, Lee MJR, Neoptolemos JP, Chan SY, Baker PR: Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer. Eur J Cancer 30A:5-11, 1994
149. Speiser P, Stolzechner J, Haider K, Heinzl H, Jakesz R, Pecherstorfer M, Rosen H, Sevelda P, Zeilliger R: pS2 protein status fails to be an independent prognostic factor in an average breast cancer population. Anticancer Res 14:2125-2130, 1994
150. Thompson A, Hawkins R, Elton R, Steel C, Chetty U, Carter D: pS2 is an independent factor of good prognosis in primary breast cancer. Br J Cancer 68:93-96, 1993
151. Clahsen P, van de Velde C, Duval C, Pallud C, Mandard A-M, Delobelle-Deroide A, van de Broek L, Sahmoud T, van de Vijver M: p53 protein accumulation and response to adjuvant chemotherapy in pre-menopausal women with node-negative early breast cancer. J Clin Oncol 16:470-479, 1998
152. Formenti S, Dunnington G, Lenz H, Russell C, Silberman H, Spicer D, Groshen S, Watkins K, Muggia F: Original p53 status predicts for pathological response to 5-fluorouracil and radiation in locally advanced breast cancer. Proc ASCO 16:A590, 1997
153. Acenero M, González J, Ballesteros P: Immunohistochemical expression of p53 and c-erbB-2 in breast carcinoma: Relation with epidemiological factors, histologic features and prognosis. Gen Diag Pathol 142:289-296, 1996
154. Eissa S, Khalifa A, El-Gharib A, Salah N, Mohamed M: Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hermone receptors for prediction of poor short term prognosis in breast cancer. Anticancer Res 17:1417-1424, 1997
155. Caffo O, Doglioni C, Veronese S, Bonzanini M, Marchetti A, Buttitta F, Fina P, Leek R, Morelli L, Dalla Palma P, Harris A, Barbareschi M: Prognostic value of p21WAF21 and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin Cancer Res 2:1591-1599, 1996
156. Charpin C, Garcia S, Bouvier C, Andrac L, Devictor B, Lavaut M-N, Allasia C, Bonnier P, Piana L: Quantitative immunocytochemical assays on frozen sections of p53. Correlation to the follow-up of patients with breast carcinomas. Anat Pathol 106:640-646, 1996
157. Katoh A, Breier S, Stemmler N, Specht S, Blanock K, D'Amico F: p53 protein expression in human breast carcinoma: lack of prognostic potential for recurrence of the disease. Anticancer Res 16:1301-1304, 1996
158. Hou M-F, Huang T-J, Huang C-J, Huang Y-S, Hsieh J-S, Lin S-J: Expression of p53 protein and its prognostic significance in breast cancer patients. Kaohsiung J Med Sci 12:471-478, 1996
159. Regidor P, Regidor M, Callies R, Schindler A: Detection of p53 auto-antibodies in the sera of breast cancer patients with new recurrence using an ELISA assay. Does a correlation with the recurrence free interval exist? Eur J Gynaec Oncol 17:192-199, 1996
160. Silvestrini R, Benini E, Daidone M, Veneroni S, Boracchi P, Cappelletti V, Di Fronzo G, Veronesi U: p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 85:965-970, 1993
161. Willsher P, Pinder S, Robertson L, Nicholson R, Ellis I, Bell J, Blamey R, Green J, Robertson J: The significance of p53 autoantibodies in the serum of patients with breast cancer. Anticancer Res 16:927-930, 1996
162. Archer S, Eliopoulos A, Spandidos D, Barnes D, Ellis I, Blamey R, Nicholson R, Robertson J: Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first-line hormonal therapy. Br J Cancer 72:1259-1266, 1995
163. Bland K, Konstadoulakis M, Vezeridis M, Wanebo H: Oncogene protein co-expression. Value of Ha-ras, c-fos, and p53 as prognostic discriminants for breast carcinoma. Ann Surg 221:706-720, 1995
164. Daidone M, Silvestrini R, Benini E, Luisi A: Biologic variables could predict specific relapse types in node-negative breast cancer. Anticancer Res 15:1825, 1995
165. Elledge R, Gray R, Mansour E, Yu Y, Clark G, Ravdin P, Osborne C, Gilchrist K, Davidson N, Robert N, Tormey D, Allred D: Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 87:1254-1256, 1995
166. Göhring U-J, Scharl A, Heckel C, Ahr A, Crombach G: p53 protein in 204 patients with primary breast carcinoma - immunohistochemical detection and clinical value as a prognostic factor. Arch Gynecol Obstet 256:139-146, 1995
167. Jansson T, Inganäs M, Sjögren S, Norberg T, Lindgren A, Holmberg L, Bergh J: p53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J Clin Oncol 13:2745-2751, 1995
168. Kristen P, Müller JG, Caffier H: Prognostic relevance of p53 in node negative breast cancer. Anticancer Res 17:2869-2871, 1997
169. Mathieu M-C, Koscielny S, Bihan M-CL, Spielmann M, Arrigada R: No relation between p53 and response to chemotherapy [letter]. Lancet 345:1182, 1995
170. Veronese S, Saladini L, Cannone M, Gamacorta M: Biological parameters and prognosis in breast cancer. Anticancer Res 15:1827, 1995
171. Koechli O, Schauer G, Selfert B, Hornung R, Haller U, Eppenberger U, Mueller H: Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet 344:1647-1648, 1994
172. Noguchi M, Kitagawa H, Kinoshita K, Thomas M, Matsuo I, Saito Y, Mizakami Y, Nonomura A, Michigishi T, Nakamura S: The relationship of p53 protein and lymph node metastases in invasive breast cancer. Surg Today 24:512-517, 1994
173. Allred D, Clark G, Elledge R, Fuqua S, Brown R, Chamness G, Osborne C, McGuire W: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85:200-206, 1993
174. Barnes D, Dublin E, Fisher C, Levinson D, Millis R: Immunohistochemical detection of p53 protein in mammary carcinoma. An important new independent indicator of prognosis? Hum Pathol 24:469-476, 1993
175. Thorlacius S, Børresen A-L, Eyfjörd J: Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. Cancer Res 53:1637-1641, 1993
176. Isola J, Visakorpi T, Holli K, Kallionemi O-P: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84:1109-1114, 1992
177. Poller D, Hutchings C, Galea M, Bell J, Nicholson R, Elston C, Blamey R, Ellis I: p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. Br J Cancer 66:583-588, 1992
178. Thor A, Moore D, Edgerton S, Kawasaki E, Reihsaus E, Lynch H, Marcus J, Schwartz L, Chen L-C, Mayall B, Smith H: Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845-855, 1992
179. Iwaya K, Tsuda H, Hiraide H, Tamaki K, Tamakuma S, Fukutomi T, Mukai K, Hirohashi S: Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res 82:835-840, 1991
180. Ostrowski J, Sawan A, Henry L, Wright C, Henry J, Henessy C, Lennard T, Angus B, Horne C: p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J Pathol 164:75-81, 1991
181. Chamness GC, Ruiz A, Fulcher L, Clark GM, McGuire WL: Stress response protein srp27 predicts recurrence in node-negative breast cancer. Breast Cancer Res Treat 12:130, 1988
182. Chamness GC, Ruiz A, Fulcher L, Clark G, Fuqua S, McGuire W: Estrogen-inducible heat shock protein hsp27 predicts recurrence in node-negative breast cancer. Proc AACR 30:252, 1989
183. kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3:222-225, 1997
184. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galuzzi C, Lavin P, Draetta G, Pagano M, Loda M: The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer 57:1259-1263, 1997
185. Panel ATME: Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 14:2843-2877, 1996
186. Sastre-Garau X, Lacombe M, Jouve M, Véron M, Magdelénat H: Nucleoside diphosphate kinase/nm23 expression in breast cancer: lack of correlation with lymph node metastasis. Int J Cancer 50:533-538, 1992
187. Tokunaga Y, Urano T, Furukawa K, Kondo H, Kanematsu T, Shiku H: Reduced expression of nm23-H1, but not of nm23-H2, is concordant with the frequency of lymph-node metastasis of human breast cancer. Int J Cancer 55:66-71, 1993
188. Barnes R, Masood S, Barker E, Rosengard A, Coggin D, Crowell T, King C, Porter-Jordan K, Wargotz E, Liotta L, Steeg P: Low nm23 protein expression in infiltrating ductal breast carcinomas correlates with reduced patient survival. Am J Pathol 139:245-250, 1991
189. Hennessy C, Henry JA, May FEB, Westley BR, Angus B, Lennard TWJ: Expression of the antimetastatic gene nm23 in human breast cancer: An association with good prognosis. J Natl Cancer Inst 83:281-285, 1991
190. Bevilacqua G, Sobel M, Liotta L, Steeg P: Association of low nm23 RNA levels in human primary infiltrating ductal carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential. Cancer Res 49:5185-5190, 1989
191. Granata G, Coradini D, Cappelletti V, DiFronzo G: Prognostic relevance of cathepsin D versus oestrogen receptors in node negative breast cancers. Eur J Cancer 27:970-972, 1991
192. Han S, Yun I, Noh D, Choe K, Song S, Chi J: Abnormal expression of four novel molecular markers represents a highly aggressive phenotype in breast cancer. Immunohistochemical assay of p53, nm23, erbB-2, and cathepsin D protein. J Surg Oncol 65:22-27, 1997
193. Namer M, Ramaioli A, Fontana X, Etienne M-C, Hery M, Jourlait A, Milano G, Frenay M, François E, Laplaus F: Prognostic value of total cathepsin D in breast tumors. A possible role in selection of chemoresistant patients. Breast Cancer Res Treat 19:85-93, 1991
194. Kute T, Shao Z-M, Sugg N, Long R, Russell G, Case L: Cathepsin D as a prognostic indicator for node negative breast cancer patients using both immuno-assays and enzymatic assays. Cancer Res 52:5198-5203, 1992
195. Spyratos F, Martin P-M, Hacène K, Romain S, Andrieu C, Ferrero-Poüs M, Deytieux S, Doussal VL, Tubiana-Hulin M, Brunet M: Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 84:1266-1272, 1992
196. Henry JA, McCarthy AL, Angus B, Westley BR, May FEB, Nicholson S, Horne CHW: Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer: An immunohistochemical study. Cancer 65:265-271, 1990
197. Alex G, Neises M, Lenz F, Melchert F: The value of new prognostic factors for the prediction of diseasefree interval for women with primary breast cancer in comparison with histopathological variables. Eur J Cancer 33:A 896, 1997
198. Itoh Y, Kobayashi S, Iwase H, Yamashita H, Kuzushima T, Iwata H, Yamashita T, Naitoh A, Itoh K, Masaoka A: Clinical significance of cathepsin D assay in breast cancer tissues. J Surg Oncol 60:221-226, 1995
199. Eng Tan P, Benz C, Dollbaum C, Moore D, Edgerton S, Zava D, Thor A: Prognostic value of cathepsin D expression in breast cancer: immunohistochemical assessment and correlation with radiometric assay. Ann Oncol 5:329-336, 1994
200. Castiglioni T, Merino M, Elsner B, Lah T, Sloane B, Emmert-Buck M: Immunohistochemical analysis of cathepsins D, B, and L in human breast cancer. Human Pathol 25:857-862, 1994
201. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, Graeff H: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24:195-208, 1993
202. Charpin C, Garcia S, Bouvier C, Martinin F, Lavaut M, Allasia C, Bonnier P, Andrac L: Cathepsin D detected by automated and quantitative immunohistochemistry in breast carcinomas: correlation with overall and disease free survival. J Clin Pathol 50:586-590, 1997
203. Göhring U-J, Scharl A, Thelen U, Crombach G, Titus B-R: Prognostic value of cathepsin D in breast cancer: comparison in immunohistochemical and immunoradiometric detection methods. J Clin Pathol 49:57-64, 1996
204. Visscher D, Sarkar F, LoRusso P, Sakr W, Ottosen S, Wykes S, Crissman J: Immunohistochemical evaluation of invasion-associated proteases in breast carcinoma. Mod Pathol 6:302-306, 1993
205. Winstanley J, Leinster S, Cooke T, Westley B, Platt-Higgins A, Rudland P: Prognostic significance of cathepsin D in patients with breast cancer. Br J Cancer 67:767-772, 1993
206. Romain S, Muracciole X, Varette I, Bressac C, Brandone H, Martin P: La cathepsine-D: un facteur prognostique indèpendant dans le cancer du sein. Bull Cancer 77:439-447, 1990
207. Jänicke F, Schmitt M, Graeff H: The urokinase-type plasminogen activator (u-PA) is related to early relapse in breast cancer. Br J Cancer s62:5, 1990
208. Grøndahl-Hansen J, Christensen I, Rosenquist C, Brünner N, Mouridsen H, Danø K, Blichert-Toft M: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53:2513-2521, 1993
209. Harbeck N, Thomssen C, Henselmann B, Dettmar P, Prechtl A, Pache L, Kuhn W, Höfler H, Jänicke F, Schmitt M, Graef H: Long-term prognostic impact of PAI-1 in primary breast cancer confirmed by six-year median follow-up. Eur J Cancer 33:A877, 1997
210. Schmitt M, Goretzki L, Jänicke F, Calvete J, Eulitz M, Kobayashi H, Chucholowski N, Graeff H: Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer. Biomed Biochim Acta 50:731-741, 1991
211. Duffy M, Duggan C, Maguire T, McDermott E, O'Higgins N: Clinical significance of urokinase plasminogen activator and its receptor in breast cancer. Eur J Cancer 33:A879, 1997
212. Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lijnen HJ: Urokinase-plasminogen activator, a marker for aggressive breast carcinomas: preliminary report. Cancer 62:531-533, 1988
213. Klijn J, Berns E, Look M, van Gelder MM, Foekens J: Relationship of p53, uPA, pS2, EGF-R, and c-erbB-2, with response to systemic treatment in recurrent breast cancer patients. Eur J Cancer 33:A886, 1997
214. Athanassiadou P, Athanassiades P, Kyrkou K, Giahnaki E, Giannioti E, Nanas S: Expression of vimentin and epidermal growth factor receptor in effusions from patients with breast cancer; correlation with oestrogen and progesterone receptor status. Cytopathology 4:91-98, 1993
215. Domagala W, Striker G, Szadowska A, Dukowicz A, Harezga B, Osborn M: p53 protein and vimentin in invasive ductal NOS breast carcinoma - relationship with survival and sites of metastases. Eur J Cancer 30A:1527-1534, 1994
216. Chenard M-P, O'Siorain L, Shering S, Rouyer N, Lutz Y, Wolf C, Basset P, Bellocq J-P, Duffy M: High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int J Cancer 69:448-451, 1996
217. Daidone M, Silvestrini R, D'Errico A, Di Fronzo G, Benini E, Mancini A, Garbisa S, Liotta L, Grigioni W: Laminin receptors, collagenase IV and prognosis in node negative breast cancers. Int J Cancer 48:529-532, 1991
218. Duffy M, Blaser J, Duggan C, McDermott E, O'Higgins N, Fennetly J, Tschesche H: Assay of matrix metalloproteases types 8 and 9 by ELISA in human breast cancer. Br J Cancer 71:1025-1028, 1995
219. Linder C, Engel G, Auer G, Strander H, Linder S: Distribution of stromelysin-3 mRNA transcripts and microvessels in human breast carcinomas. Breast Cancer Res Treat 42:207-213, 1997
220. Russo A, Bazan V, Morello V, Tralongo V, Nagar C, Nuara R, Dardanoni G, Bazan P, Tomasino R: Vimentin expression, proliferating cell nuclear antigen and flow cytometric factors: prognostic role in breast cancer. Anal Quant Cyt Hist 16:364-374, 1994
221. Seshadri R, Raymond W, Leong A, Horsfall D, McCaul K: Vimentin expression is not associated with poor prognosis in breast cancer. Int J Cancer 67:353-356, 1996
222. Stonelake P, Hail C, Jevons C, Baker P, Baker P: Proteinases and other prognostic markers in breast cancer. Br J Cancer 69:A83, 1994
223. Perin T, Canzonieri V, Massarut S, Bidoli E, Rossi C, Roncadin M, Carbone A: Immunohistochemical evaluation of multiple biological markers in ductal carcinoma in situ of the breast. Eur J Cancer 12A:1148-1155, 1996
224. Pellegrini R, Martignone S, Tagliabue E, Belotti D, Bufalino R, Cascinelli M, Mènard S, Colnaghi M: Prognostic significance of laminin production in relation with its receptor expression in human breast carcinomas. Breast Cancer Res Treat 35:195-199, 1995
225. Martignone: Prognostic significance of the 67-kilodalton laminin receptor expression in human breast carcinomas. J Natl Cancer Inst 85:398-402, 1993
226. Marques LA, Franco EL, Torloni H, Brentani MM, Baptista da Silva-Neto J, Brentani RR: Prognostic value of laminin receptor expression in breast cancer survival. Cancer Res 50:1479-1483, 1990
227. Colnaghi M, Cascinelli N, Rilke F, Ménard S, Bufalino R, Andreola S, Martignone S, Greco M, Mascheroni L, Testori A: Predicting potential of c-erbB-2 oncoprotein and laminin receptor expression on primary breast cancer. Eur J Cancer 29A suppl 6:S31, 1993
228. Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991
229. Horak ER, Leek R, Klenk N, Lejeune S, Smith K, Stuart N, Greenall M, Stepniewska K, Harris AL: Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340:1120-1124, 1992
230. Gasparini G, Fox SB, Verderio P: Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients. Clin Cancer Res 2:1191-1198, 1996
231. Gasparini G: Clinical significance of the determination of angiogenesis in human breast cancer: Update of the biological background and overview of the Vicenza studies. Eur J Cancer 32A:2485-2493, 1996
232. Axelsson K, Ljung B-M, Moore D, Thor A, Chew K, Edgerton S, Smith H, Mayall B: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 87:997-1007, 1995
233. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred E, Moore D, Meli S, Gasparini G: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875-1888, 1992
234. Weidner N, Folkman J: Tumor vascularity as a prognostic factor in cancer. Principles and Practice of Oncology Updates 11:24, 1997
235. Vermeulen P, Libura J, Libura M, Hellemans P, Van Marck E, van Oosterom A, Dirix L: Re: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma [letter]. J Natl Cancer Inst 87:1797-1798, 1995
236. Fox S, Gatter K, Altman D, Leek R, Harris A: Re: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma [letter]. J Natl Cancer Inst 87:1798-1799, 1995
237. Gasparini G: Re: Tumor angiogenesis as a prognostic assay in invasive ductal carcinoma [Letter]. J Natl Cancer Inst 87:1799-1801, 1995
238. Axelsson K, Ljung B-M, Chew K, Mayall B, Moore D, Smith H, Thor A, Edgerton S: Re: Tumor angiogenesis as a prognostic assay in invasive ductal carcinoma [letter]. J Natl Cancer Inst 87:1801-1802, 1995
239. Heimann R, Ferguson D, Powers C, Recant W, Weichselbaum R, Hellman S: Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J Natl Cancer Inst 88:1764-1769, 1996
240. Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P, Gatti C, Suzuki H, Tominaga T: Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89:139-145, 1997
241. Toi M, Kashitani J, Tominaga T: Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 55:371-374, 1993
242. Bosari S, Lee A, DeLellis R, Wiley B, Heatley G, Silverman M: Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 23:755-761, 1992
243. Vartanian R, Weidner N: Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. Am J Pathol 144:1188-1194, 1994
244. Weidner N, Gasparini G: Determination of epidermal growth factor receptor provides additional prognostic information to measuring tumor angiogenesis in breast carcinoma patients. Breast Cancer Res Treat 29:97-107, 1994
245. Toi M, Inada K, Suzuki H, Tominaga T: Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with endothelial growth factor expression. Breast Cancer Res Treat 36:193-204, 1995
246. Siitonen S, Haapasalo H, Rantala I, Helin H, Isola J: Comparison of different immunohistochemical methods in the assessment of angiogenesis: lack of prognostic value in a group of 77 selected node-negative breast carcinomas. Mod Pathol 8:745-752, 1995
247. McCulloch P, Choy A, Martin L: Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery. Lancet 346:1334-1335, 1995
248. Ellis L, Fidler I: Angiogenesis and breast cancer metastasis. Lancet 346:388-389, 1995
249. Goulding H, Rashid N, Robertson J, Bell J, Elston C, Blamey R, Ellis I: Assessment of angiogenesis in breast carcinoma: an important factor in prognosis? Hum Pathol 26:1196-1200, 1995
250. Relf M, LeJeune S, Scott P, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris A: Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet derived endothelial celt growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57:963-969, 1997
251. Salvén P, Joensuu H, Heikkilä P, Matikainen M-T, Wasenius V-M, Alanko A, Alitalo K: Endothelial TIE growth factor provides antigenic marker for assessment of breast cancer angiogenesis. Br J Cancer 74:69-72, 1996
252. Toi M, Hoshima S, Takayanagi T, Tominaga T: Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 85:1045-1049, 1994
253. Lee W-J, Chu J-S, Houng S-J, Chung M-F, Wang S-M, Chen K-M: Breast cancer angiogenesis: A quantitative morphologic and doppler imaging study. Ann Surg Oncol 2:246-251, 1995
254. Gasparini G, Barbareschi M, Boracchi P, Bevilacqua P, Verderio P, Dalla Palma P, Ménard S: 67-kDa laminin-receptor expression adds prognostic information to intra-tumoral microvessel density in node-negative breast cancer. Int J Cancer 60:604-610, 1995
255. Obermair A, Kurtz C, Czerwenka K, Thoma M, Kaider A, Wagner T, Gitsch G, Selveda P: Micro-vessel density and vessel invasion in lymph-node-negative breast cancer: Effect on recurrence-free survival. Int J Cancer 62:126-131, 1995
256. Kato T, Kinura T, Miyakawa R, Tanaka S, Fujii A, Yamamoto K, Kameoka S, Hamano K, Kawakami M, Aiba M: Clinicopathologic study of angiogenesis in Japanese patients with breast cancer. World J Surg 21:49-56, 1997
257. Paulsen T, Aas T, Borresen A-L, Varhaug J, Lønning P, Akslen L: Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. Int J Cancer 74:138-140, 1997
258. Morphopolous G, Pearson M, Ryder W, Howell A, Harris M: Tumour angiogenesis as a prognostic marker in infiltrating lobular carcinoma of the breast. J Pathol 180:44-49, 1996
259. Simpson J, Ahn C, Battifora H, Esteban J: Endothelial area as a prognostic indicator for invasive breast carcinoma. Cancer 77:2077-2085, 1996
260. Bevilacqua P, Barbareschi M, Verderio P, Boracchi P, Caffo O, Dalla Palma P, Meli S, Weidner N, Gasparini G: Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma - results of a multiparametric study. Breast Cancer Res Treat 36:205-217, 1995
261. Costello P, McCann A, Carney D, Dervan P: Prognostic significance of microvessel density in lymph node negative breast carcinoma. Hum Pathol 26:1181-1194, 1995
262. Fox S, Leek R, Weekes M, Whitehouse R, Gatter K, Harris A: Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol 177:275-283, 1995
263. Karaiosifidi H, Kouri E, Arvaniti H, Sfikas S, Vasilaros S: Tumor angiogenesis in node-negative breast cancer: Relationship with relapse-free survival. Anticancer Res 16:4001-4002, 1996
264. Fox S, Turner G, Leek R, Whitehouse R, Gatter K, Harris A: The prognostic value of quantitative angiogenesis in breast cancer and role of adhesion molecule expression in tumor endothelium. Breast Cancer Res Treat 36:219-226, 1995
265. Gasparini G, Harris A: Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool. J Clin Oncol 13:765-782, 1995
266. Hall N, Fish D, Hunt N, Goldin R, Guillou P, Monson J: Is the relationship between angiogenesis and metastasis in breast cancer real? Surg Oncol 1:223-229, 1992
267. Ogawa Y, Chung Y-S, Nakata B, Takatsuka S, Maede K, Sawade T, Kato Y, Yoshikawa K, Sakurai M, Sowa M: Microvessel quantitation in invasive breast cancer: staining for factor VIII-related antigen. Br J Cancer 71:1297-1301, 1995
268. Liotta L, Saidel G, Kleinerman J: The significance of intravascular tumor cell clumps in the metastatic process. Cancer Res 36:889-894, 1976
269. Smolin G, Hyundiuk R: Lymphatic drainage from vascularized rabbit cornea. Am J Opthamol 72:147-151, 1971
270. Viens P, Bertolucci F, Sun Z, Penault Llorca F, Bardou V, Geneix J, Jacquemier J: p53 overexpression and tumor angiogenesis are associated with treatment failure in women with breast cancer treated by a standard dose adjuvant chemotherapy. Proc AACR 38:A1579, 1997
271. Barnes D, Dublin E, Smith P, Miles DW, Rubens RD: Stabilized p53 protein and outcome following adjuvant CMF in 277 women with mammary carcinoma. Proc AACR 38:A1581, 1997
272. Fox S, Westwood M, Moghaddam A, Comley M, Turley H, Whitehouse R, Bicknell R, Gatter K, Harris A: The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endo-thelium. Br J Cancer 73:275-280, 1996
273. Obermair A, Kucera E, Mayerhofer K, Speiser P, Seifert M, Czerwenka K, Kaider A, Leodolter S, Kainz C, Zeillinger R: Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival. Int J Cancer 74:455-458, 1997
274. Dirix L, Vermeulen P, Pawinski A, Prové A, Benoy I, de Pooler C, Martin M, van Oosterom A: Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 76:238-243, 1997
275. Bonneterre J, Peyrat J, Beuscart R, Demaille A: Prognostic significance of insulin-like growth factor-1 receptors in human breast cancer. Cancer Res 50:6931-6935, 1990
276. Railo M, van Smitten K, Pekonen F: The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients. Eur J Cancer 30A:307-311, 1994
277. Berns E, Klijn J, van Staveren I, Portengen H, Foekens J: Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors. Cancer Res 52:1036-1039, 1992
278. Liu F-F, Miller N, Levin W, Zanke B, Cooper B, Henry M, Sherrar M, Pintlie M, Hunt J, Hill R: The potential role of HSP70 as an indicator of response to radiation and hyperthermia treatments for recurrent breast cancer. Int J Hypertherm 12:197-208, 1996
279. Love S, King R: A 27 kDa heat shock protein that has anomalous prognostic powers in early and advanced breast cancer. Br J Cancer 69:743-748, 1994
280. Tandon AK, Clark GM, Chamness GC, Fuqua SAW, Welch WJ, Riehl RM, McGuire WL: Heat shock/stress response proteins: biological and clinical significance in breast cancer. Proc ASCO 9:23, 1990
281. Solomayer E-F, Diel I, Gollan C, Wallweiner D, Gisecke F, Kaul S, Basert G: Tumor cell detection in breast cancer patients before and after neoadjuvant chemotherapy. Eur J Cancer 33:A342, 1997
282. Depenni R, Federico M, Morselli M, Luppi M, Cagossi K, Barbieri F, Torelli G, Silingardi V: Detection of circulating breast cancer cells by RT-PCR of maspin gene: the mobilising effect of conventional chemotherapy. Proc ASCO 16:A487, 1997
283. Diel I, Gollan C, Wallweiner D, Basert G: Prognostic impact of minimal residual disease in patients with early breast cancer. Eur J Cancer 33:A340, 1997
284. Fox S, Leek R, Bliss J, Mansi J, Gusterson B, Gatter K, Harris A: Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients. J Natl Cancer Inst 89:1044-1049, 1997
285. Mansi J, Berger U, Easton D, MacDonnell T, Redding W, Gazet J-C, McKinna A, Powles T, Coombes C: Micrometastases in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastases. Br Med J 295:1093, 1987
286. Ménard S, Squicciarini P, Luini A, Sacchini V, Rovini D, Tagliabue E, Veronesi P, Salvadori B, Veronesi U, Colnaghi M: Immunodetection of bone marrow metastases in breast carcinoma patients and its correlation with primary tumour prognostic features. Br J Cancer 66:1126-1129, 1994
287. Marcus J, Page D, Watson P, Narod S, Lenoir G, Lynch H: BRCA1 and BRCA2 hereditary breast carcinoma phenotypes. Cancer 80:543-556, 1997
288. Jóhannsson O, Ranstam J, Borg Å, Olsson H: Survival of BRCA1 breast and ovarian cancer patients: A population-based study from southern Sweden. J Clin Oncol 16:397-404, 1998
289. Krainer M, Silva-Arrieta S, Fitzgerald M, Shimada A, Ishioka C, Kanamaru R, MacDonald D, Unsal H, Finkelstein D, Bowcock A, Isselbacher K, Haber D: Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med 336:1416-1421, 1997
290. Eisinger F, Lyonnet DS, Longy M, et al: Germ line mutation at BRCA1 affects histoprognostic grade in hereditary breast cancer. Cancer Res 56:471-474, 1996
291. Marcus J, Watson P, Page D, Narod S, Lenoir G, Tonin A, Linder-Stephenson L, Salerno G, Conway T, Lynch H: Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 77:697-709, 1996
292. Lynch H, Marcus J, Watson P, Page D: Distinctive clinicopathological features of BRCA-1 linked hereditary breast cancer. Proc ASCO 13:A27, 1994